CJC-1295 NO DAC 10mg is a synthetic research peptide studied in laboratory and preclinical models involving growth hormone-releasing hormone (GHRH) receptor signaling, growth hormone secretion pathways, and the GH/IGF-1 axis.
CJC-1295 NO DAC is commonly used to describe the non-DAC form of a modified GHRH fragment, meaning it does not contain the Drug Affinity Complex (DAC) modification associated with the longer-acting form of CJC-1295. This distinction is important when evaluating the compound in experimental research because the absence of DAC materially affects its molecular characteristics and pharmacokinetic behavior.
CJC-1295 NO DAC 10mg is supplied strictly for laboratory research and analytical investigation. It is not intended for human or animal consumption, clinical use, diagnostic use, therapeutic use, or veterinary use.
Research Specifications
|
|
| Product Name |
CJC-1295 NO DAC |
| Vial Quantity |
10mg |
| Form |
Lyophilized Powder |
| Research Classification |
Synthetic GHRH Analog Research Peptide |
| Primary Research Target |
GHRH Receptor |
| Peptide Length |
29 Amino Acids |
| Research Pathway |
Growth Hormone / IGF-1 Signaling |
| DAC Modification |
No |
| Intended Use |
Laboratory Research Only |
GHRH Receptor Research
CJC-1295 NO DAC has been investigated as a synthetic analog of growth hormone-releasing hormone, a signaling peptide involved in regulation of the growth hormone axis.
GHRH interacts with the growth hormone-releasing hormone receptor (GHRHR), a G-protein-coupled receptor expressed primarily in pituitary somatotroph cells. Activation of this receptor initiates intracellular signaling involved in growth hormone synthesis and secretion.
Modified GHRH analogs provide researchers with tools for examining this receptor system and the downstream biochemical pathways associated with growth hormone signaling.
Growth Hormone Signaling Research
A primary area of research involving CJC-1295 NO DAC concerns the mechanisms regulating growth hormone secretion.
Growth hormone release is controlled through a complex neuroendocrine system involving stimulatory and inhibitory signals. GHRH represents one of the principal stimulatory components of this system.
Laboratory investigation of GHRH analogs allows researchers to examine receptor activation, signaling dynamics, secretory responses, and other characteristics of the growth hormone regulatory pathway under controlled experimental conditions.
GH/IGF-1 Axis Research
The growth hormone pathway is closely associated with the insulin-like growth factor 1 (IGF-1) axis.
Growth hormone signaling can influence downstream IGF-1 production and numerous related cellular signaling pathways. As a result, modified GHRH compounds have been studied experimentally to better understand relationships between upstream GHRH receptor activity and downstream GH/IGF-1 signaling.
Research involving these pathways remains experimental and should not be interpreted as establishing therapeutic or clinical effects.
CJC-1295 NO DAC vs. CJC-1295 DAC
The distinction between CJC-1295 NO DAC and CJC-1295 DAC is particularly important in research.
CJC-1295 with DAC incorporates a Drug Affinity Complex, which was developed to facilitate binding to circulating albumin and substantially extend the compound’s persistence.
The research material commonly called CJC-1295 NO DAC does not contain this modification. Consequently, the non-DAC compound exhibits substantially different molecular and pharmacokinetic characteristics from DAC-modified CJC-1295.
Researchers should therefore distinguish between CJC-1295 NO DAC and CJC-1295 DAC when interpreting experimental literature, analytical documentation, and study results.
Molecular Research Profile
CJC-1295 NO DAC is generally associated in the research marketplace with a 29-amino-acid modified GHRH fragment.
Because terminology surrounding CJC-1295 NO DAC, modified GRF (1-29), and CJC-1295 has historically been used inconsistently across research and commercial sources, molecular identifiers should be interpreted carefully.
For this reason, exact molecular formula, molecular weight, sequence, and CAS information should be matched against the specific chemical identity identified by applicable batch documentation rather than assumed solely from the CJC-1295 NO DAC product name.
Lyophilized Research Peptide
CJC-1295 NO DAC 10mg is supplied in lyophilized powder form for laboratory research.
Lyophilization removes water from the material under controlled conditions, producing a stable dry research format suitable for storage and subsequent laboratory preparation according to established research protocols.
Batch-specific analytical documentation may be available to provide additional information regarding the identity and purity of the research material.
Research Use Only
CJC-1295 NO DAC 10mg is intended strictly for laboratory research purposes only.
This product is not intended for human consumption, animal consumption, clinical use, diagnostic use, therapeutic use, veterinary use, or for the treatment, cure, mitigation, or prevention of any disease.
